<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-8 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-8</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-8</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of specific brain cell types reported as most susceptible or most resilient in Alzheimer's disease, along with where and when this was observed, how it was measured, quantitative results, proposed mechanisms (including genetic risk enrichment), modifiers (e.g., sex, APOE), contradictions, and any causal/perturbational evidence.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>cell_type_name</strong></td>
                        <td>str</td>
                        <td>The precise cell type reported (e.g., 'EC layer II stellate neuron', 'CA1 pyramidal neuron', 'RORB+ IT excitatory neuron', 'somatostatin interneuron', 'parvalbumin interneuron', 'microglia', 'astrocyte', 'oligodendrocyte', 'OPC', 'endothelial', 'pericyte', 'cholinergic basal forebrain neuron', 'locus coeruleus noradrenergic neuron').</td>
                    </tr>
                    <tr>
                        <td><strong>cell_subtype_or_state</strong></td>
                        <td>str</td>
                        <td>Any reported subtype or disease-associated state (e.g., 'RORB+ IT L4/5', 'disease-associated microglia (DAM)', 'A1/A2 astrocyte', 'oligodendrocyte stress state', 'VIP+', 'SST+').</td>
                    </tr>
                    <tr>
                        <td><strong>cell_class</strong></td>
                        <td>str</td>
                        <td>Broad class: excitatory neuron, inhibitory neuron, astrocyte, microglia, oligodendrocyte, OPC, endothelial, pericyte, ependymal, vascular smooth muscle, etc.</td>
                    </tr>
                    <tr>
                        <td><strong>markers_or_genes</strong></td>
                        <td>str</td>
                        <td>Key marker genes or proteins used to define the cell type/state (e.g., RORB, SMI-32/NEFH, TREM2, APOE, GFAP, MBP, PDGFRa, TH).</td>
                    </tr>
                    <tr>
                        <td><strong>brain_region_and_layer</strong></td>
                        <td>str</td>
                        <td>Brain region and laminar/nuclear detail where the finding was observed (e.g., 'entorhinal cortex layer II', 'hippocampus CA1', 'superior temporal gyrus layer 4', 'visual cortex V1', 'basal forebrain', 'locus coeruleus').</td>
                    </tr>
                    <tr>
                        <td><strong>species_or_model</strong></td>
                        <td>str</td>
                        <td>Species and/or disease model (e.g., 'human postmortem AD', '5xFAD mouse', 'APP/PS1 mouse', 'P301S tau', 'iPSC-derived neurons', 'nonhuman primate').</td>
                    </tr>
                    <tr>
                        <td><strong>disease_stage_or_braak</strong></td>
                        <td>str</td>
                        <td>Stage of disease or pathology burden (e.g., preclinical, MCI, early/late AD, Braak stage, Thal phase, CERAD/ABC score).</td>
                    </tr>
                    <tr>
                        <td><strong>susceptibility_label</strong></td>
                        <td>str</td>
                        <td>Categorize the cell type's status in the study: 'susceptible', 'resilient', 'mixed/region-specific', or 'no effect'.</td>
                    </tr>
                    <tr>
                        <td><strong>measurement_type</strong></td>
                        <td>str</td>
                        <td>Assay/approach used to infer susceptibility or resilience (e.g., snRNA-seq differential abundance, spatial transcriptomics, stereology, immunohistochemistry, EM, in vivo imaging, proteomics, bulk RNA-seq deconvolution).</td>
                    </tr>
                    <tr>
                        <td><strong>quantitative_change</strong></td>
                        <td>str</td>
                        <td>Key quantitative result(s) supporting susceptibility/resilience, with numbers and units where available (e.g., '% cell loss', 'log2 fold-change in abundance', 'odds ratio', 'density per mm^2', 'distance to plaque/tangle', 'change in soma size').</td>
                    </tr>
                    <tr>
                        <td><strong>pathology_measured</strong></td>
                        <td>str</td>
                        <td>Pathology assessed in relation to the cell type (e.g., amyloid-β plaques, tau tangles, neuritic plaques, synapse loss, gliosis, neurodegeneration/atrophy).</td>
                    </tr>
                    <tr>
                        <td><strong>associations_with_pathology</strong></td>
                        <td>str</td>
                        <td>Reported associations/correlations with pathology metrics (e.g., correlation with tangle density, proximity to plaques; include r/p-values if present).</td>
                    </tr>
                    <tr>
                        <td><strong>spatial_or_proximity_context</strong></td>
                        <td>str</td>
                        <td>Any spatial context of the finding (e.g., 'enriched within 50 μm of plaques', 'laminar-specific loss', 'perivascular').</td>
                    </tr>
                    <tr>
                        <td><strong>mechanism_hypothesis</strong></td>
                        <td>str</td>
                        <td>Proposed mechanisms explaining susceptibility/resilience (e.g., calcium handling, long-projecting axons, metabolic demand, myelination/oligodendrocyte support, proteostasis, mitochondrial dysfunction, endosomal trafficking, receptor expression patterns).</td>
                    </tr>
                    <tr>
                        <td><strong>ad_gwas_gene_enrichment</strong></td>
                        <td>str</td>
                        <td>Any reported enrichment of AD GWAS risk genes or pathways in the cell type/state (e.g., APOE, TREM2, BIN1, CLU; include enrichment stats if provided).</td>
                    </tr>
                    <tr>
                        <td><strong>perturbation_or_causal_evidence</strong></td>
                        <td>str</td>
                        <td>Evidence from genetic or pharmacological perturbations that alter susceptibility/resilience in this cell type (e.g., TREM2 knockout effects, APOE isoforms, tau overexpression; specify direction of effect).</td>
                    </tr>
                    <tr>
                        <td><strong>modifiers_and_risk_factors</strong></td>
                        <td>str</td>
                        <td>Reported modifiers: sex differences, APOE genotype, age, ancestry, vascular risk, lifestyle factors; and their interactions with the cell type's vulnerability/resilience.</td>
                    </tr>
                    <tr>
                        <td><strong>comorbid_pathologies</strong></td>
                        <td>str</td>
                        <td>Presence/effects of non-AD co-pathologies (e.g., TDP-43, Lewy bodies, vascular disease) influencing conclusions for this cell type.</td>
                    </tr>
                    <tr>
                        <td><strong>comparisons_to_other_cell_types</strong></td>
                        <td>str</td>
                        <td>Direct comparisons within the study to other cell types/subtypes indicating relative susceptibility/resilience.</td>
                    </tr>
                    <tr>
                        <td><strong>contradictory_or_null_findings</strong></td>
                        <td>str</td>
                        <td>Any conflicting or null results reported in the same paper or cited from other studies regarding this cell type.</td>
                    </tr>
                    <tr>
                        <td><strong>replication_or_cross_cohort_validation</strong></td>
                        <td>str</td>
                        <td>Evidence that the finding replicates across datasets/assays/cohorts or external validation (brief description).</td>
                    </tr>
                    <tr>
                        <td><strong>sample_size_and_counts</strong></td>
                        <td>str</td>
                        <td>Numbers of subjects/samples and cells/nuclei analyzed relevant to this finding (e.g., n donors, n cells).</td>
                    </tr>
                    <tr>
                        <td><strong>dataset_or_platform</strong></td>
                        <td>str</td>
                        <td>Sequencing/imaging platform or dataset name (e.g., 10x Genomics, SMART-Seq, Visium, Slide-seq, MERFISH; or named consortia/datasets).</td>
                    </tr>
                    <tr>
                        <td><strong>functional_impact</strong></td>
                        <td>str</td>
                        <td>Reported functional consequences linked to the cell type change (e.g., synaptic transmission deficits, network oscillation changes, cognitive correlations).</td>
                    </tr>
                    <tr>
                        <td><strong>key_evidence_snippet</strong></td>
                        <td>str</td>
                        <td>A concise quote or paraphrased sentence from the paper that encapsulates the main evidence for susceptibility/resilience of this cell type.</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>